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ABSTRACT 
 
                Left ventricular hypertrophy (LVH) and increases in large artery stiffness predict 
cardiovascular outcomes in patients with renal failure. What determines left ventricular mass 
index (LVMI) and large artery stiffness and the contribution toward LVH and large artery 
dysfunction is not entirely clear. Consequently, this cross sectional study was aimed at 
assessing the various factors impacting on LVH in haemodialysis (HD), to contribute toward 
our understanding of the pathophysiology of LVH and large artery dysfunction in 94 adult HD 
patients. Pre- and post-dialysis blood pressures (BPs) were determined over 12 sessions of 
dialysis and averaged. Pulse wave analysis performed at the carotid, femoral and radial 
arteries was employed to determine pulse wave velocity (PWV) and central augmentation 
index (AIc). Echocardiography was performed to determine left ventricular mass (LVM) 
indexed to body surface area (LVMI). Natriuretic peptides, procollagen type I c-peptide (PIP), 
c-terminal telopeptide of type I collagen (ICTP), matrix metalloproteinases and their inhibitors 
were studied. 
                The prevalence of LVH was 72.8 % (67/92) .On multivariate analysis pre- (p≤ 
0.005), post- (p<0.05) and averaged dialysis (p < 0.015) systolic BP were associated with 
LVMI and PWV.  24 hour (r = 0.260, p = 0.026), day (r = 0.247, p = 0.036), and night (r= 
0.241, p = 0.042) systolic BP were not more closely associated with LVMI than the averaged 
dialysis systolic BP (r = 0.272, p = 0.010). Similarly 24 hour (r = 0.41, p = 0.0003), day 
(r=0.400, p = 0.0005), and night (r =0.416, p = 0.0003) systolic BP were not more closely 
associated with PWV than the post-dialysis systolic BP (r=0.39, p=0.0001) indicating that 
these BP measurements are as effective as 24-hour ambulatory BP in predicting cardiovascular 
 
 
 
 
 
vi
target organ changes. No relationship between either PWV (r=-0.08), or AIc (r=-0.10) and 
LVMI, between PWV (r=-0.11), or AIc (r=0.03) and LV MWT was noted. IVCD was 
independently associated with LVMI (partial r adjusted for average dialysis SBP=0.27, 
p=0.014; partial r adjusted for 24-hour SBP=0.29, p=0.013), and LV mean wall thickness 
(p<0.01), but not with LV relative wall thickness (p=0.18), or LV end diastolic diameter 
(p=0.88). An association between IVCD and AIc (partial r adjusted for average dialysis 
SBP=0.21, p<0.05), but not PWV was noted. NT-proANP and NT-proBNP were 
independently associated with LVMI (p<0.0001) but neither were associated with IVCD 
independent of LVMI suggesting a close association with LVMI in HD. Serum concentrations 
of matrix metalloproteinases 1, 2 and 9, and their tissue inhibitors (1 and 2) were not 
associated with LVMI, remodelling or PWV and neither procollagen I nor the C-terminal 
telopeptide of type I collagen (ICTP) were associated with LVMI. Thus, factors impacting on 
LVH in this study were systolic BP, NT-proANP, NT-proBNP and IVCD. 
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PREFACE 
 
The incidence of cardiovascular disease in chronic kidney disease population has been 
described as reaching epidemic proportions. Cardiovascular mortality in patients on renal 
replacement therapy is 10–30 times more common than in the general population. Left 
ventricular hypertrophy (LVH) and large artery dysfunction are prevalent intermediate 
cardiovascular changes in patients receiving HD. Volume and pressure related risk factors 
impact LVH and large artery dysfunction. Measurements of circulating natriuretic peptides 
and their N-terminal pro-hormones and inferior vena cava diameter (IVCD) have been used 
recently to aid in assessment of appropriate circulating volume. Studies have suggested that 
changes in collagen I markers, matrix metalloproteinase 1, 2, 9 and their tissue inhibitors (1 
and 2) may predict changes in the cardiovascular system. However, what is not entirely clear 
is exactly what determines these, and the extent to which each factor contributes toward LVH 
and large artery dysfunction in HD.  
 
 
 
 
 
 
